Study on COgnition and Prognosis in the Elderly (SCOPE): Baseline characteristics

Blood Pressure

Volumn 9, Issue 2-3, 2000, Pages 146-151

  Hansson, Lennart ^a   Lithell, H ^b   Skoog, I ^b   Baro, F ^b   Banki C M ^b   Breteler, M ^b   Castaigne, A ^b   Correia, M ^b   Degaute, J P ^b   Elmfeldt, D ^b   Engedal, K ^b   Farsang, C ^b   Ferro, J ^b   Hachinski, V ^b   Hofman, A ^b   James, O F W ^b   Krisin, E ^b   Leeman, M ^b   De Leeuw, P W ^b   Leys, D ^b   Lobo, A ^b   Nordby, G ^b   Olofsson, B ^b   Opolski, G ^b   Prince, M ^b   Reischies, F M ^b   Rosenfeld, J B ^b   Ruilope, L ^b   Salerno, J ^b   Tilvis, R ^b   Trenkwalder, P ^b   Zanchetti, A ^b   more..

^a UPPSALA UNIVERSITY   (Sweden)

^b NONE

Author keywords

Candesartan cilexetil; Cognitive function; Elderly; Mild hypertension

Indexed keywords

CANDESARTAN HEXETIL; ENALAPRIL; HYDROCHLOROTHIAZIDE; NITRENDIPINE;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ELDERLY CARE; FEMALE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 0034119826     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370500453483999     Document Type: Article

References (27)

1. Burt VL, Culter JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26: 60-9.
2. Trenkwalder PR. STEPHY II (Starnberg Study on Epidemiology of Parkinsonism and Hypertension). Clin Cardiol 1998; 21: 129-30.
3. Kannel WB, Gordan T. Evaluation of cardiovascular risk in the elderly: the Framingham study. Bull N Y Acad Med 1978; 54: 573-91.
4. Vokonas PS, Kannel WB, Cupples LA. Epidemiology and risk of hypertension in the elderly: the Framingham study. J Hypertens 1988; 63 Suppl 6: S3-S9.
5. Kannel WB. Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Am Heart J 1999; 138 (3 Pt 2): 205-10.
6. Insua JT, Sacks HS, Lau T-S, et al. Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 1994; 121: 355-362.
7. Dahlöf B, Lindholm LH, Hansson L. Scherstén B, Ekbom T, Wester P-O. Mortality and morbidity in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-5.
8. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program. JAMA 1991; 265: 3255-64.
9. Fagard RH, Staessen JA. Treatment of isolated systolic hypertension in the elderly: the Syst-Eur trial. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Clin Exp Hypertens 1999; 21: 491-7.
10. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992: 304-12.
11. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Scherstén B, Wester P-O, Hedner T, de Faire U, for the STOP-Hypertension-2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6.
12. Holzgreve H, Middeke M. Treatment of hypertension in the elderly. Drugs 1993; 46 Suppl 2: 24-31.
13. Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-5.
14. Hansson L, Lithell H, Skoog I, et al. Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Press 1999; 8: 177-83.
15. Aevarsson O, Skoog I. A longitudinal population study on the Mini Mental State Examination in the very old. Relation to dementia and education. Dementia: in press.
16. Tombaugh TN, McIntyre NJ. The Mini Mental State Examination: a comprehensive review. J Am Geriatr Soc 1992; 40: 922-935.
17. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347-51.
18. Souetre EJ, Qing W, Vigoureux I, et al. Economic analysis of Alzheimer's disease in outpatients: impact of symptom severity. Int J Psychogeriatr 1995; 7: 115-22.
19. van den Bosch JH, Kardaun JW. Ziektelast door aandoeningen van het zenuwstelsel in Nederland. [Disease burden of nervous system disorders in The Netherlands.] Ned Tiidschr Geneeskd 1994; 138: 1219-24.
20. Ernst RL, Hay JW, Fenn C, Tinklenberg J, Yesavage JA. Cognitive function and the costs of Alzheimer disease. An exploratory study. Arch Neurol 1997; 54: 687-93.
21. Elmfeldt D, George M, Hübner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997; 11 Suppl 2: S49-S53.
22. Belcher G, Hubner R, George M, Elmfeldt D, Lunde H. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1997; 11 Suppl 2: S85-9.
23. Lacourcière Y, Asmar R for the candesartan/losartan study investigators. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients. A placebo-controlled, forced titration study. Am J Hypertens 1999; 12: 1181-87.
24. McInnes GT, O'Kane KP, Jonker J, Roth J. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997; 11 Suppl 2: S75-80.
25. 3H]acetylcholine from rat entorhinal cortex in vitro. Brain Res 1989; 492: 136-43.
26. Barnes NM, Champaneria S, Costall B, Kelly ME, Murphy DA, Naylor RJ. Cognitive enhancing actions of DUP 753 detected in a mouse habituation paradigm. Neuroreport 1990; 1: 239-42.
27. Barnes NM, Costall B, Kelly ME, Murphy DA, Naylor RJ. Cognitive enhancing actions of PD 123177 detected in a mouse habituation paradigm. Neuroreport 1991; 2: 351-3.